EU reconsidering CureVac deal following study - report

Sunday, 20. June 2021 15:46

Some European Union Member States are pushing for the cancellation of the agreement with CureVac N.V. on delivering coronavirus vaccines to the block following the company's vaccine effectiveness study, German media reported on Sunday.

According to the report, the Member States were sceptical of CureVac's vaccine even before the study, courtesy of the vaccine's delayed development, but the results of the study, showing that the vaccine was at most 47% effective in adults younger than 60 and inconclusive for anyone older, are expected to increase the pressure on the Commission to potentially negate the contract.

However, the bloc's governing body is reportedly waiting for the European Medicines Agency (EMA) to approve the vaccine or not before making the final call, and it is currently unknown whether the EU would have to pay for the CureVac doses it ordered in advance.

Related Links: Curevac N.V.
Breaking the News / OL